Dr. Toriola’s research focuses on characterizing the molecular basis and determinants of mammographic breast density that are targetable, especially in premenopausal women, and to translate study findings to breast cancer prevention, through clinical trials. He is the PI on an NIH/NCI funded phase II clinical trial investigating the effect of RANKL inhibition on mammographic breast density and breast tissue/blood markers in premenopausal women with dense breasts (R37CA235602: https://clinicaltrials.gov/ct2/show/NCT04067726). In addition, he performs molecular epidemiologic studies on colorectal and pancreatic cancers, evaluating the utility of biomarkers to investigate the associations of energetics, and inflammation with risk/mortality. He is an MPI on the ColoCare Study (U01 CA206110: https://clinicaltrials.gov/ct2/show/NCT02328677), a large multicenter cohort of colorectal cancer (CRC) patients for interdisciplinary studies of CRC prognosis and outcomes.
- 1998: MD, Obafemi Awolowo University, Ile-Ife, Nigeria
- 2007: MPH, University of Kuopio, Kuopio, Finland
- 2011: PhD, epidemiology, University of Tampere, Tampere, Finland
- 2011 - 2012: Fellow, German Cancer Research Center, Heidelberg, Germany
Disclaimer: This listing may not include all articles associated with this physician and may include publications related to other physicians with a similar name.